While Food and Drug Administration staff said the drug is effective, they focused on safety concerns in a review of dapagliflozin released Friday ahead of a Tuesday FDA advisory panel meeting in Silver Spring, Md. Bristol-Myers and AstraZeneca, which has its U.S. headquarters in Fairfax, have said they expect a final decision on approval by Oct. 28.
Posted via email from Jack's posterous
Source: http://pharmagossip.blogspot.com/2011/07/az-diabetes-drug-may-cause-cancer-news.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.